Rebuttal: Is a Nihilistic Approach to Thrombophilia Screening Justified?

• References

• 1 Levine M, Hirsh J, Gent M. et al. Optimal duration of oral anticoagulant therapy: a randomised trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
• 2 Crowther MA, Roberts J, Roberts R. et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85 (03) 390-394.
• 3 Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
• 4 Eichinger S, Pabinger I, Stumpflen A. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-8.
• 5 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 6 Lindmarker P, Schulman S, Sten-Linder M. et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-9.
• 7 Eichinger S, Minar E, Hirschl M. et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 14-7.
• 8 Martinelli I, Mannucci P, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2352-8.
• 9 Simioni P, Sanson B, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
• 10 Sanson B-J, Simioni P, Tormene D. et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C or protein S: a prospective cohort study. Blood 1999; 94: 3702-6.
• 11 Simioni P, Tormene D, Prandoni P. et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99 (06) 1938-42.
• 12 Brill-Edwards P, Ginsberg JS, Gent M. et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343 (20) 1439-44.
• 13 Simioni P, Tormene D, Prandoni P, Girolami A. Pregnancy-related recurrent events in thrombophilic women with previous venous thromboembolism. Thromb Haemost 2001; 86 (03) 929.
• 14 Eekhoff EM, Rosendaal FR, Vandenbroucke JP. Minor events and the risk of deep venous thrombosis. Thromb Haemost 2000; 83 (03) 408-11.
• 15 Pabinger I, Schneider B. for the GTH Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C or protein S deficiency. Arterioscler Thromb Vasc Biol 1996; 16: 742-8.
• 16 Clark P, Twaddle S, Walker ID, Scott L, Greer IA. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359: 1919-20.
• 17 Summarised in. Greaves M, Preston FE. Chapter 48: Approach to the bleeding patient. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JG. eds. Lippincott: Williams and Wilkins; 2001
• 18 British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114 (03) 512-28.